The Risk-Sharing Agreement (RSA) reevaluations for term renewal are underway for Imfinzi Inj (durvalumab, AZ), which applied for reimbursement extensions to its biliary tract cancer indication.

The reevaluations are being conducted in preparation for the RSA contract renewal set for March next year.

According to industry sources on the 14th, AstraZeneca Korea recently submitted the pharmacoeconomic evaluation data for Imfinzi to the Health Insurance Review and Assessment Service for RSA renewals.

Korea's RSA system requires companies to submit PE evaluation data for reevaluation within 1 year of RSA term expiry.

The company signed an RSA for Imfinzi,